Gelesis Holdings, Inc. GLS
Set alert
0.16 0.00 0.00%
At close · Apr 10
0.145 Day range 0.1622
52-week range unavailable
- Open
- 0.15
- Prev close
- 0.1586
- Mkt cap
- 11.63M
- Vol
- 185.17K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.145
- High
- 0.1622
- Forward P/E
- -0.59
- Beta
- 0.99
- Short ratio
- 3.37
- Inst. own
- 29.38%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 28, 2023
- 50-d avg
- 0.183248
- 200-d avg
- 0.612698
- 1y target
- 0.45
Key statistics
- Market cap
- 11.63M
- Enterprise value
- 79.03M
- Trailing P/E
- 0.00
- Forward P/E
- -0.59
- PEG ratio
- 0.00
- Price / sales
- 0.45
- Price / book
- 0.00
- EPS (TTM)
- -1.30
- Beta
- 0.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -216.48%
- Revenue (TTM)
- 25.77M
- Revenue growth
- -9.10%
- Free cash flow
- -58.60M
- Total cash
- 7.41M
- Total debt
- 62.26M
- Return on equity
- 0.00%
- Shares outstanding
- 73.33M
- Short % of float
- 2.53%
- 50-day average
- 0.183248
- 200-day average
- 0.612698
Analyst view
Consensus: hold
Hold
Price target (mean) 0.45
Next earnings
Mar 28, 2023
Expected Mar 28, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 28, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Apr 22, 2010 | Mar 1, 2010 | 0.15 | — | — | — |
| Feb 25, 2010 | Dec 1, 2009 | 0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 20, 2022 | Citigroup | init | — | Neutral |
About Gelesis Holdings, Inc.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gelesis.com
News
- GLS Italy strengthens its network of pick-up points in partnership with Quadient
- Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
- Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
- Cell Reports Medicine Publication Demonstrates How Gelesis' Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies
- Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Wednesday
- Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
- Why TuanChe Shares Are Trading Lower By 76%? Here Are 48 Stocks Moving In Monday's Mid-Day Session
- Gelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call Transcript
- Gelesis Reports Third Quarter 2022 Results
Your note
Sign in to keep a note on GLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABRAHAM DAVID J.D. | General Counsel | Stock Award(Grant) | May 5, 2022 | 256,437 |
| CAVANAUGH KATHRYN | Director | Stock Award(Grant) | May 5, 2022 | 61,639 |
| CHIQUETTE ELAINE PHARM.D. | Officer | Stock Award(Grant) | Jun 7, 2022 | 263,079 |
| CHRISTOPHER CLAYTON | Director | Stock Award(Grant) | May 5, 2022 | 510,768 |
| FONTEYNE PAUL R | Director | Stock Award(Grant) | May 5, 2022 | 53,832 |
| KUCHERLAPATI RAJU S | Director | Purchase | Nov 20, 2022 | 190,264 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.02% | 2,944,423 | 466.99K | Dec 30, 2022 |
| Allianz Asset Management GmbH | 3.50% | 2,563,876 | 406.63K | Dec 30, 2022 |
| Vitruvian Partners, LLP | 2.56% | 1,876,106 | 297.55K | Dec 30, 2022 |
| Neuberger Berman Group, LLC | 1.51% | 1,107,985 | 175.73K | Dec 30, 2022 |
| Blackrock Inc. | 1.09% | 799,156 | 126.75K | Dec 30, 2022 |
| Northeast Financial Consultants Inc | 0.54% | 395,035 | 62.65K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.39% | 2,478,100 | 393.03K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.54% | 394,479 | 62.56K | Sep 29, 2022 |
| iShares Russell 2000 Value ETF | 0.24% | 175,699 | 27.86K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.17% | 126,692 | 20.09K | Nov 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 74,300 | 11.78K | Sep 29, 2022 |
| Schwab Capital Trust-Small Cap Index Fund | 0.05% | 35,034 | 5.56K | Oct 30, 2022 |